Results 101 to 110 of about 16,883 (239)

Evaluation of Dolutegravir- and Bictegravir-Based Antiretroviral Regimen Utilization in Patients who Cannot Take Medications by Mouth [PDF]

, 2023
Megan LoFaso, Olivia Marchionda, Stephanie Bass, Heather Torbic, Caitlin Blackewicz, Andrea Pallotta   +5 more
openalex   +1 more source

Dolutegravir [PDF]

Reactions Weekly, 2020
  +4 more sources

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.

The Lancet HIV, 2023
T. Loosli, Stefanie Hossmann, Suzanne M Ingle, H. Okhai, K. Kusejko, Johannes Mouton, P. Bellecave, A. van Sighem, M. Stecher, Antonella d'Arminio Monforte, M. Gill, C. Sabin, G. Maartens, H. Günthard, J. A. Sterne, R. Lessells, M. Egger, R. Kouyos   +17 more
semanticscholar   +1 more source

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context

EClinicalMedicine
Summary: Background: Dolutegravir and bictegravir are frequently prescribed second-generation integrase strand transfer inhibitors. Although sex and gender influence drug pharmacokinetics, little is known about the differences in side effects ...
Zhou Fang, Tetiana Povshedna, Rowan Patterson, Erin Ready, Helene C.F. Cote, Melanie C.M. Murray, Elizabeth M. King   +6 more
doaj   +1 more source

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine [PDF]

, 2018
Stephen Walimbwa, Mohammed Lamorde, Catriona Waitt, Julian Kaboggoza, Laura Else, Pauline Byakika‐Kibwika, Alieu Amara, Joshua Gini, Markus Winterberg, Justin Chiong, Joel Tärning, Saye Khoo   +11 more
openalex   +1 more source

Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries [PDF]

, 2023
Matthew L. Romo, Allahna Esber, John Owuoth, Jonah Maswai, Valentine Sing’oei, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, Joseph S. Cavanaugh, Neha Shah, Julie A. Ake, Trevor A. Crowell, the AFRICOS Study Group   +12 more
openalex   +1 more source

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

, 2020
Steve Kanters, Marco Vitória, Michael J. Zoratti, Meg Doherty, Martina Penazzato, Ajay Rangaraj, Nathan Ford, Kristian Thorlund, Prof. Aslam H. Anis, Mohammad Ehsanul Karim, Lynne Mofenson, Rebecca Zash, Alexandra Calmy, Tamara Kredo, Nick Bansback   +14 more
openalex   +1 more source

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients [PDF]

, 2015
C. Gubavu, Thiérry Prazuck, Mohamadou Niang, J. Buret, Catherine Mille, Jérôme Guinard, Véronique Avettand-Fènoël, Laurent Hocqueloux   +7 more
openalex   +1 more source

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study

AIDS Research and Treatment
Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants.
Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu   +11 more
doaj   +1 more source